Redacted is an independent platform, unencumbered by external factors or restrictive policies, on which Clayton and Natali Morris bring you quality information, balanced reporting, constructive debate, and thoughtful narratives.

Pfizer says that profit for 2023 will be down due to low demand for the Covid vaccine.

“We are in the middle of the Covid fatigue. Nobody wants to speak about Covid,” Pfizer CEO Albert Bourla said during a recent earnings call. “We have the big anti-vaccination rhetoric.”

Pfizer estimates an annual profit for 2023 of somewhere between $58-61 billion. Previous forecasts were  between $67-70 billion. A Pfizer report says that this drop is “solely due to its Covid products” such as the new vaccine and Pfizer’s antiviral drug. The CDC estimates that only 2% of Americans have received the most recent Covid booster shot.

While $70 billion does not seem all that bad for a profit report, consider that Pfizer made over $100 billion last year from Covid products. Because of this drop, Pfizer says that it will have to resort to cost-cutting measures which includes layoffs starting next year.

Related Articles

Join the Redacted Community

Don’t miss out on the latest news and in-depth stories. Subscribe to Redacted newsletter for daily insights that matter, delivered directly to your inbox.

Related Articles